T. Rowe Price Associates
MRVI icon

T. Rowe Price Associates’s Maravai LifeSciences MRVI Stock Holding History

T. Rowe Price Associates’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
177,501
+36,735
+26% +$159K ﹤0.01% 2279
2026
Q1 		$399K Buy
140,766
+24,773
+21% +$84K ﹤0.01% 2545
2025
Q4 		$377K Hold
115,993
– – ﹤0.01% 2528
2025
Q3 		$333K Buy
115,993
+27,000
+30% +$68.9K ﹤0.01% 2554
2025
Q2 		$215K Buy
88,993
+6,170
+7% +$13K ﹤0.01% 2679
2025
Q1 		$184K Buy
82,823
+11,995
+17% +$47.4K ﹤0.01% 2679
2024
Q4 		$387K Buy
70,828
+7,946
+13% +$51.1K ﹤0.01% 2394
2024
Q3 		$523K Buy
62,882
+1,019
+2% +$8.81K ﹤0.01% 2227
2024
Q2 		$443K Sell
61,863
-11,732
-16% -$101K ﹤0.01% 2236
2024
Q1 		$639K Buy
73,595
+3,575
+5% +$24.2K ﹤0.01% 2110
2023
Q4 		$459K Sell
70,020
-16,087
-19% -$104K ﹤0.01% 2213
2023
Q3 		$862K Sell
86,107
-889,663
-91% -$9.77M ﹤0.01% 1868
2023
Q2 		$12.1M Buy
975,770
+1,030
+0.1% +$13.9K ﹤0.01% 1044
2023
Q1 		$13.7M Buy
974,740
+4,215
+0.4% +$60.5K ﹤0.01% 1002
2022
Q4 		$13.9M Sell
970,525
-328,840
-25% -$5.18M ﹤0.01% 994
2022
Q3 		$33.2M Sell
1,299,365
-348,262
-21% -$8.74M 0.01% 760
2022
Q2 		$46.8M Sell
1,647,627
-401,330
-20% -$12.7M 0.01% 896
2022
Q1 		$72.3M Buy
2,048,957
+102,221
+5% +$3.43M 0.01% 840
2021
Q4 		$81.6M Buy
1,946,736
+418,203
+27% +$16.9M 0.01% 832
2021
Q3 		$75M Buy
1,528,533
+675,951
+79% +$33M 0.01% 872
2021
Q2 		$35.6M Buy
852,582
+517,893
+155% +$20.1M ﹤0.01% 1147
2021
Q1 		$11.9M Buy
+334,689
New +$11.1M ﹤0.01% 1369

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

T. Rowe Price Associates's MRVI Position: Q2 2026 in Review

T. Rowe Price Associates increased its Maravai LifeSciences (MRVI) stake by 26% in Q2 2026, buying an estimated $159K and bringing the position to 177,501 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2279.

T. Rowe Price Associates first reported a position in MRVI in Q1 2021 and has held it in 22 quarters since. The position peaked at $81.6M in Q4 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • T. Rowe Price Associates held 177,501 shares of Maravai LifeSciences worth $1.11M as of Q2 2026.
  • T. Rowe Price Associates bought 36,735 Maravai LifeSciences shares in Q2 2026, an estimated $159K.
  • Maravai LifeSciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2279 holding.
  • T. Rowe Price Associates first reported a position in Maravai LifeSciences in Q1 2021 and has held it in 22 quarters since.
  • T. Rowe Price Associates's Maravai LifeSciences position peaked at $81.6M in Q4 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.